Wall Street rallies as dental laser maker Biolase raises $12 million through a private placement round, even as the company deals with an ongoing civil war involving ousted CEO Federico Pignatelli.
California-based Biolase (NSDQ:BIOL) announced today that it secured $12 million in a private placement funding round, even as the company weathers the internal tumult following the ouster of former CEO Federico Pignatelli.
A new Federal Circuit Court ruling means Align Technology can move forward with a patent infringement case against rival ClearCorrect.
Dental devices maker Align Technology (NSDQ:ALGN) touted a Federal Circuit Court ruling issued this month, calling it a "total win for Align."
A federal judge dismisses a whistleblower lawsuit accusing McKesson of encouraging Medicare fraud and getting rid of workers who opposed the scheme.
San Francisco-based healthcare giant McKesson (NYSE:MCK) dodged a Medicare fraud lawsuit this week after a federal judge ruled that prospective whistleblower Leslie Ann Williams didn't have enough evidence to support her accusations.
Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects "wrongdoing, mismanagement and corporate governance failures."
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company's management under the suspicion of wrongdoing.
Biolase CEO Federico Pignatelli is out after a court-ordered shake-up at Biolase.
The boardroom and C-suite at Biolase (NSDQ:BIOL) got a shake-up this week following a Delaware Supreme Court decision in a lawsuit filed by Oracle Partners earlier this year.
Biolase vows to amend its complaint after a federal judge shoots down its false advertising and defamation claims against rival dental laser maker Fotona.
A federal judge this month dismissed a Biolase (NSDQ:BIOL) lawsuit alleging false advertising and defamation by dental laser rival Fotona, but left the door open for an amended complaint.
Oracle Partners issues a public statement to announce its "disappointment" over Biolase's Q1 results, which Biolase chairman & CEO Federico Pignatelli says is more evidence of the firm's attempts to take over the dental devices company.